Artículo
A Novel Synergistic Combination of Cyclophosphamide and Gene Transfer of Interleukin-12 Eradicates Colorectal Carcinoma in Mice
Malvicini, Mariana ; Rizzo, Manglio Miguel
; Rizzo, Manglio Miguel ; Alaniz, Laura; Piñero, Federico; García, Mariana Gabriela
; Alaniz, Laura; Piñero, Federico; García, Mariana Gabriela ; Atorrasagasti, María Catalina
; Atorrasagasti, María Catalina ; Aquino, Jorge Benjamin
; Aquino, Jorge Benjamin ; Rozados, Viviana Rosa
; Rozados, Viviana Rosa ; Scharovsky, Olga Graciela
; Scharovsky, Olga Graciela ; Matar, Pablo
; Matar, Pablo ; Mazzolini Rizzo, Guillermo Daniel
; Mazzolini Rizzo, Guillermo Daniel 
 ; Rizzo, Manglio Miguel
; Rizzo, Manglio Miguel ; Alaniz, Laura; Piñero, Federico; García, Mariana Gabriela
; Alaniz, Laura; Piñero, Federico; García, Mariana Gabriela ; Atorrasagasti, María Catalina
; Atorrasagasti, María Catalina ; Aquino, Jorge Benjamin
; Aquino, Jorge Benjamin ; Rozados, Viviana Rosa
; Rozados, Viviana Rosa ; Scharovsky, Olga Graciela
; Scharovsky, Olga Graciela ; Matar, Pablo
; Matar, Pablo ; Mazzolini Rizzo, Guillermo Daniel
; Mazzolini Rizzo, Guillermo Daniel 
Fecha de publicación:
12/2009
Editorial:
American Association for Cancer Research
Revista:
Clinical Cancer Research
ISSN:
1078-0432
Idioma:
								Inglés
							
Tipo de recurso:
							Artículo publicado
							
Clasificación temática:
Resumen
Purpose: Interleukin-12 (IL-12) is an immunostimulatory cytokine with potent antitumor effects in several animal models. However, serious toxicity has been associated with its systemic application in humans. Gene transfer has emerged as a tool to specifically express therapeutic genes into the tumor/peritumoral milieu, thus avoiding systemic toxicity. The aim of this study was to analyze whether subtherapeutic doses of an adenovirus encoding IL-12 (AdIL-12) might synergize with low immunopotentiating doses of cyclophosphamide in the treatment of colorectal carcinoma. Experimental Design: The antitumor effect of combining a single low dose of cyclophosphamide with an intratumoral injection of AdIL-12 was evaluated in an in vivo murine colorectal carcinoma model. The immune responses achieved with different treatments were monitored, comparing the effect of combining both therapies with individual treatments. Results: The combined therapy induced a complete tumor regression in >50% of mice in a synergistic fashion, and it significantly prolonged their survival. This strategy was superior to each single treatment in reducing both peripheral and splenic CD4+CD25+Foxp3+ regulatory T cells, increasing the number of activated dendritic cells, and inducing IFNγ-secreting CD4-positive T lymphocytes. Importantly, the combined treatment generated a powerful tumor-specific CTL response. Consistently, a significant reduction in IL-10 levels was found. Our data suggest that the combination of nontoxic doses of cyclophosphamide with AdIL-12 allows the generation of good antitumoral responses, thus avoiding undesired side effects of both agents. Conclusions: Our data strongly support the use of a combination of cyclophosphamide and AdIL-12 as a novel therapeutic strategy against colorectal carcinoma. (Clin Cancer Res 2009;15(23):7256–65)
Palabras clave:
Cyclophosphamide
                            ,
	                    
IL12
                            ,
	                    
Colorectal Carcinoma
Archivos asociados
Licencia
Identificadores
	                Colecciones
	                
Articulos(CCT - ROSARIO)
Articulos de CTRO.CIENTIFICO TECNOL.CONICET - ROSARIO
Articulos de CTRO.CIENTIFICO TECNOL.CONICET - ROSARIO
Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL
Articulos de SEDE CENTRAL
	                Citación
	                
Malvicini, Mariana; Rizzo, Manglio Miguel; Alaniz, Laura; Piñero, Federico; García, Mariana Gabriela; et al.; A Novel Synergistic Combination of Cyclophosphamide and Gene Transfer of Interleukin-12 Eradicates Colorectal Carcinoma in Mice; American Association for Cancer Research; Clinical Cancer Research; 15; 23; 12-2009; 7256-7265
	                Compartir
	                
	                Altmétricas
	                
 
 
 
 
